Myeloid hematopoietic growth factors and their role in prevention and/or treatment of neonatal sepsis**

https://doi.org/10.1053/tmrv.2002.29348Get rights and content

Sepsis continues to be an important cause of morbidity and mortality among both full-term and preterm infants, secondary to an immaturity in neonatal host defense. The incidence of neonatal sepsis ranges from 30% in very low birth weight infants to 0.4% in preterm neonates and 0.1% in term neonates. The dysregulation of the expression and production of hematopoietic cytokines in the neonate contributes to quantitative and qualitative deficiencies in neonatal myeloid progenitor activity and decreased availability and function of mature effector neutrophils. These abnormalities contribute in large part to the increased incidence and mortality associated with neonatal sepsis. In this review, we have summarized and analyzed the studies investigating the dysregulation, expression and production of myelopoietic growth factors in neonates, the preclinical in vivo effects of myelopoietic growth factors in neonatal animals, the preclinical in vivo effects of myelopoietic growth factors during experimental sepsis in neonatal animals, the in vitro effects of growth factors on human neonatal phagocytic immunity, and clinical results of myelopoietic growth factors in human neonates. Future studies should be focused on investigating other abnormalities of neonatal host defense and multiple and simultaneous approaches to circumvent identified defects to attempt to reduce both the incidence and severity of neonatal host defense

References (68)

  • BrandtJ et al.

    Role of c-kit ligand in the expansion of human hematopoietic progenitor cells

    Blood

    (1992)
  • BernsteinID et al.

    Recombinant human stem cell factor enhances the formation of colonies by CD34 and CD34 lin-cells, and the generation of colonyforming cell progeny from CD34 lin cells cultured with interleukin-3, granulocyte colony-stimulating factor, or granulocyte-macrophage colony-stimulating factor

    Blood

    (1991)
  • CarowCE et al.

    Mast cell growth factor (c-kit ligand) supports the growth of human multipotential progenitor cells with a high replating potential

    Blood

    (1991)
  • CairoMS et al.

    Effect of stem cell factor with and without granulocyte colony-stimulating factor on neonatal hematopiesis: In vivo induction of newborn myelopoiesis and reduction of mortality during experimental group B streptococcal sepsis

    Blood

    (1992)
  • ChangM et al.

    Transforming growth factor-β1, macrophage inflammatory protein-1α, and interleukin-8 gene expression is lower in stimulated human neonatal compared to adult mononuclear cells

    Blood

    (1994)
  • CairoMS et al.

    Seven-day administration of recombinant human granulocyte colony-stimulating factor to newborn rats: Modulation of neonatal neutrophilia, myelopoiesis, and group B streptococcus sepsis

    Blood

    (1990)
  • ChangM et al.

    Endogenous interleukin-11 (IL-11) expression is increased and prophylactic use of exogenous IL-11 enhances platelet recovery and improves survival during thrombocytopenia associated with experimental group B streptococcal sepsis in neonatal rats

    Blood Cells, Molecules, Dis

    (1996)
  • FleischmannJ et al.

    Granulocyte-macrophage colony-stimulating factor enhances phagocytosis of bacteria by human neutrophils

    Blood

    (1986)
  • AndersonDC et al.

    Abnormal stimulated adherence of neonatal granulocytes: impaired induction of surface Mac-1 by chemotactic factors or secretagogues

    Blood

    (1987)
  • GillanER et al.

    A randomized, placebo-controlled trial of recombinant human granulocytecolony stimulating factor administration in newborn infants with presumed sepsis: significant induction of peripheral and bone marrow neutrophilia

    Blood

    (1994)
  • CairoMS et al.

    Results of a phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor in very low birthweight neonates: significant induction of circulatory neutrophils, monocytes, platelets and bone marrow neutrophils

    Blood

    (1995)
  • CairoMS et al.

    A randomized, doubleblind, placebo-controlled trial of prophylactic recombinant human granulocyte-macrophage colony-stimulating factor to reduce nosocomial infections in very low birth weight neonates

    J Pediatr

    (1999)
  • PolinR et al.

    Neonatal sepsis

    Adv Pediatric Infect Dis

    (1992)
  • St. GemeJW et al.

    Neonatal Sepsis. Progress in diagnosis and management

    Drugs

    (1988)
  • BoyerKM et al.

    Selective intrapartum chemoprophylaxis of neonatal group B streptococcal early-onset disease. I. Epidemiologic rationale

    J Infect Dis

    (1983)
  • BoyerKM et al.

    Prevention of early-onset neonatal group B streptococcal disease with selective intrapartum chemoprophylaxis

    N Engl J Med

    (1986)
  • PolinRA et al.
  • SidiropoulosD et al.

    Immunoglobulin supplementation in prevention or treatment of neonatal sepsis

    Pediatr Infect Dis

    (1986)
  • HaqueKN et al.

    IgM-enriched intravenous immunoglobulin therapy in neonatal sepsis

    Am J Dis Child

    (1988)
  • FriedmanCA et al.

    Intravenous gamma globulin as adjunct therapy for severe group B streptococcal disease in the newborn

    Am J Perinatol

    (1990)
  • FanaroffA et al.

    A controlled trial of prophylactic intravenous immunoglobulin (IVIG) to reduce nosocomial infections in VLBW infants

    Pediatr Res

    (1992)
  • HaqueKN et al.

    Intravenous immunoglobulin for prevention of sepsis in preterm and low birth weight infants

    Pediatr Infect Dis

    (1986)
  • BakerCJ et al.

    Intravenous immune globulin for the prevention of nosocomial infection in low-birth-weight neonates. The Multicenter Group for the Study of Immune Globulin in Neonates

    N Engl J Med

    (1992)
  • LaurentiF et al.

    Polymorphonuclear leukocyte transfusion for the treatment of sepsis in the newborn infant

    J Pediatr

    (1981)
  • Cited by (0)

    **

    Supported in part by a grant from the Pediatric Cancer Research Foundation

    View full text